Conversely, in the ATV/r100 arm, grade 3 treatment-related adverse events included increased blood bilirubin (26% [14/53]), increased aspartate transaminase (2% [1/53]), increased triglycerides (2% [1/53]), and hyperbilirubinemia (11%; 6/53]), and grade 4 treatment-related events included increased bilirubin (2% [1/53]) and increased alanine transaminase (2% [1/53]). Here, GPT is linked to Hyperbilirubinemia.